Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Shaikh, Saba S; Zang, Yan; Hanmer, Janel; Wang, Hong; Lin, Yan; Davar, Diwakar; Zarour, Hassane M; Kirkwood, John M; Najjar, Yana G.

Afiliación

Shaikh SS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.
Zang Y; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Hanmer J; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Wang H; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
Lin Y; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States.
Davar D; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States.
Zarour HM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Kirkwood JM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Najjar YG; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.